Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 133

1.

Midkine Deteriorates Cardiac Remodeling via Epidermal Growth Factor Receptor Signaling in Chronic Kidney Disease.

Honda Y, Shishido T, Takahashi T, Watanabe T, Netsu S, Kinoshita D, Narumi T, Kadowaki S, Nishiyama S, Takahashi H, Arimoto T, Miyamoto T, Kishida S, Kadomatsu K, Takeishi Y, Kubota I.

Hypertension. 2016 May;67(5):857-65. doi: 10.1161/HYPERTENSIONAHA.115.06922. Epub 2016 Mar 14.

PMID:
26975703
2.

Tempol, a Superoxide Dismutase-Mimetic Drug, Ameliorates Progression of Renal Disease in CKD Mice.

Ding W, Wang B, Zhang M, Gu Y.

Cell Physiol Biochem. 2015;36(6):2170-82. doi: 10.1159/000430183. Epub 2015 Jul 21.

PMID:
26279424
3.

GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective.

Adela R, Banerjee SK.

J Diabetes Res. 2015;2015:490842. doi: 10.1155/2015/490842. Epub 2015 Jul 27. Review.

4.
5.

Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells.

Morgado-Pascual JL, Rayego-Mateos S, Valdivielso JM, Ortiz A, Egido J, Ruiz-Ortega M.

Biomed Res Int. 2015;2015:783538. doi: 10.1155/2015/783538. Epub 2015 May 6.

6.

Comparison of epitheliotrophic factors in autologous serum eyedrops from sera of chronic renal failure patients vs. normal controls.

Kang NH, Lee S, Jun RM.

Graefes Arch Clin Exp Ophthalmol. 2015 Oct;253(10):1705-12. doi: 10.1007/s00417-015-3056-5. Epub 2015 May 31.

PMID:
26026935
7.

Identification of a receptor for extracellular renalase.

Wang L, Velazquez H, Chang J, Safirstein R, Desir GV.

PLoS One. 2015 Apr 23;10(4):e0122932. doi: 10.1371/journal.pone.0122932. eCollection 2015.

8.

Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure.

Gandhi PU, Gaggin HK, Belcher AM, Harisiades JE, Basile A, Falco A, Rosati A, Piscione F, Januzzi JL Jr, Turco MC.

Clin Chim Acta. 2015 May 20;445:73-8. doi: 10.1016/j.cca.2015.02.048. Epub 2015 Mar 6.

PMID:
25753466
9.

Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).

Launay-Vacher V, Aapro M, De Castro G Jr, Cohen E, Deray G, Dooley M, Humphreys B, Lichtman S, Rey J, Scotté F, Wildiers H, Sprangers B.

Ann Oncol. 2015 Aug;26(8):1677-84. doi: 10.1093/annonc/mdv136. Epub 2015 Mar 3. Review.

PMID:
25735315
10.
11.

SREBP-1 Mediates Angiotensin II-Induced TGF-β1 Upregulation and Glomerular Fibrosis.

Wang TN, Chen X, Li R, Gao B, Mohammed-Ali Z, Lu C, Yum V, Dickhout JG, Krepinsky JC.

J Am Soc Nephrol. 2015 Aug;26(8):1839-54. doi: 10.1681/ASN.2013121332. Epub 2014 Nov 14.

PMID:
25398788
12.

Exocyst Sec10 protects renal tubule cells from injury by EGFR/MAPK activation and effects on endocytosis.

Fogelgren B, Zuo X, Buonato JM, Vasilyev A, Baek JI, Choi SY, Chacon-Heszele MF, Palmyre A, Polgar N, Drummond I, Park KM, Lazzara MJ, Lipschutz JH.

Am J Physiol Renal Physiol. 2014 Dec 15;307(12):F1334-41. doi: 10.1152/ajprenal.00032.2014. Epub 2014 Oct 8.

13.

Renal cortical hexokinase and pentose phosphate pathway activation through the EGFR/Akt signaling pathway in endotoxin-induced acute kidney injury.

Smith JA, Stallons LJ, Schnellmann RG.

Am J Physiol Renal Physiol. 2014 Aug 15;307(4):F435-44. doi: 10.1152/ajprenal.00271.2014. Epub 2014 Jul 2.

14.

ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease.

Beck Gooz M, Maldonado EN, Dang Y, Amria MY, Higashiyama S, Abboud HE, Lemasters JJ, Bell PD.

Am J Physiol Renal Physiol. 2014 Sep 1;307(5):F551-9. doi: 10.1152/ajprenal.00218.2014. Epub 2014 Jun 4.

15.

Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy.

Ponnusamy M, Zhou X, Yan Y, Tang J, Tolbert E, Zhao TC, Gong R, Zhuang S.

J Pharmacol Exp Ther. 2014 Aug;350(2):243-56. doi: 10.1124/jpet.113.212076. Epub 2014 May 15.

16.

Class I HDAC activity is required for renal protection and regeneration after acute kidney injury.

Tang J, Yan Y, Zhao TC, Gong R, Bayliss G, Yan H, Zhuang S.

Am J Physiol Renal Physiol. 2014 Aug 1;307(3):F303-16. doi: 10.1152/ajprenal.00102.2014. Epub 2014 May 7.

17.

HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction.

Zewinger S, Speer T, Kleber ME, Scharnagl H, Woitas R, Lepper PM, Pfahler K, Seiler S, Heine GH, März W, Silbernagel G, Fliser D.

J Am Soc Nephrol. 2014 May;25(5):1073-82. doi: 10.1681/ASN.2013050482. Epub 2014 Mar 7.

18.

The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation.

Talbot JJ, Song X, Wang X, Rinschen MM, Doerr N, LaRiviere WB, Schermer B, Pei YP, Torres VE, Weimbs T.

J Am Soc Nephrol. 2014 Aug;25(8):1737-48. doi: 10.1681/ASN.2013091026. Epub 2014 Feb 27.

19.

Complete metabolic remission with Gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer.

Del Conte A, Minatel E, Schinella D, Baresic T, Basso SM, Lumachi F.

Anticancer Res. 2014 Jan;34(1):319-22.

PMID:
24403481
20.

[Impact of renal dysfunction on clinical course of myocardial infarction complicated by acute heart failure in patients with preserved systolic function].

Parkhomenko OM, Hur"ieva OS, Kornatskyĭ IuV, Kozhukhov SM, Sopko OO.

Fiziol Zh. 2013;59(4):80-7. Ukrainian.

PMID:
24175481
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk